Ruxolitinib plus photopheresis shows promise for steroid-refractory chronic graft-versus-host disease
New Hope for Stubborn Transplant Complication
A retrospective analysis compared ruxolitinib plus extracorporeal photopheresis versus photopheresis alone in patients with steroid-refracto…
This combo may help patients reduce or stop steroid use — a major win for quality of life.
Review explores JAK inhibitor combination with PD-1 blockade for overcoming immunotherapy resistance
Review explores combining JAK inhibitors with immunotherapy for resistant cancers
A systematic review discusses the rationale for combining JAK inhibitors with PD-1 blockade immunotherapy based on emerging preclinical and …
Blocking inflammation around tumors with JAK inhibitors may help immune drugs work better for cancers that have stopped responding to standa…
Phase 3 trial of navitoclax plus ruxolitinib versus ruxolitinib alone in myelofibrosis posts results
Phase 3 trial tests navitoclax with ruxolitinib for myelofibrosis spleen volume
A phase 3 randomized controlled trial in 252 adults with myelofibrosis compared navitoclax plus ruxolitinib to ruxolitinib plus placebo. The…
A new drug combination aims to shrink painful enlarged spleens in myelofibrosis patients, but results from this large global trial are not y…